UCLH

London WC1E 6AG

2 studies enrolling now · 4 studies all time

What they study most

HER2-positive Breast Cancer, IDH1-mutant Cholangiocarcinoma, Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen, Urinary Incontinence, Urge

Studies at this site

• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma — Stopped early
• Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt — Completed